

Core Facility Genomics

versatile genome or transcriptome analyses

based on quantifiable highthroughput

data ascertainment



Topics

Collaboration with Harald Binder and Clemens Kreutz

Project:

Microarray Validation of Cardiovascular Risk Factors (NGFN)


Principal Investigator: Prof. Dr. G. Walz

Collaborator: Prof. Dr. R. Baumeister / Prof. Dr. J. Timmer

Technologies and application spectra of the Core Facility Genomics

(Sample processing / Data analysis (QC) / Statistical analysis)

Workflow



Study Population

Collecting blood samples from 324 patients

RNA Isolation

Follow up study

Data acquisition of all relevant clinical data

Printing and Hybridization

Printing of the human Unigene Set - RZPD 3.1 (RZPD-Nr. 983)
37 358 human cDNA clones → two slides

**Amplification of the RNA samples using the
Ambion Kit (aRNA)**

Sample RNA labelling = Cy3 (green)
Universal Reference (Human) = Cy5 (red)
↓
log-ratio of measured Cy3/Cy5 intensities

Stringency Criteria

Clemens Kreutz, Institute of Physics

Starting with \approx 12 103 992 data points

Normalization and flagging based on the Genedata Software (Refiner)

Filter criteria (stringent):

- **Rejection of saturated data points / genes (Intensity > 65 000)**
- **Rejection of genes with more than 50% missing data (samples)**
- **Signal / Noise Ratio > 2 (Foreground > Background)**
- **Maximum relative Error < 0.2 (standard deviation / mean x number of pixels)**

2 882 888 data points do not fulfil the stringency criteria

Grouping based on clinical covariates

Group-1

living (221) versus died (100)

Group-2

no coronary heart disease (117)

versus

coronary heart disease (160)

Group-3

living with no coronary heart disease (97)

versus

died by coronary heart disease (30)

Number of regulated Genes

Group-1 (living versus died)

fold > 1.5 = 20	fold < 1.5 = 15
p-value < 0.05 and fold > 1.5 = 14	p-value < 0.05 and fold < 1.5 = 9

Group-2 (no CHD versus CHD)

fold > 1.5 = 9	fold < 1.5 = 11
p-value < 0.05 and fold > 1.5 = 2	p-value < 0.05 and fold < 1.5 = 5

Group-3 (living with no CHD versus died by CHD)

fold > 1.5 = 96	fold < 1.5 = 17
p-value < 0.05 and fold > 1.5 = 78	p-value < 0.05 and fold < 1.5 = 13

Comparing different kinds of Cases!!!

**Cardiovascular Disease (CVD)
Polygenic Multifactorial Disease**

**Dialysis Patients
Population with high risk for CVD**

Epigenetics

Genetics

Environment

**One and the same clinical phenotype
in two patients (e.g. CHD)
but different history !!!**

**Different history could lead to
inhomogeneous expression profile
within two patients with the
same clinical phenotype**

Predictive Modeling / Harald Binder, FDM

Subdivision of the study population based on risk strata into low risk (25%), middle risk (50%) and high risk (25%) individuals

low risk (81) versus high risk (81)

fold > 1.5 = 602

fold < 1.5 = 281

p-value < 0.05 and fold > 1.5 = 579

p-value < 0.05 and fold < 1.5 = 276




p-FDR < 0.05 and fold > 1.5 = 567

p-FDR < 0.05 and fold < 1.5 = 276

Grouping based on survival analyses lead to more homogenous groups !!!

Technologies and application spectra of the Core Facility Genomics



Genome → **Transkriptome** → **Proteome** → **Organism**



Printing microarrays



cDNA Library



Printing

75 μ m/250nl

**Agilent InkJet Printing Technology breakthrough
- Sensitivity and Flexibility**



Advantages

- Free content selection
- High sensitivity
- Cost efficient

Agilent Platform



Genome Analysis

- **Tiling Arrays: 1 x 244K, 2 x 105K, 4 x 44K, 8 x 15K**
- **Comparative Genomic Hybridization (CGH)**
- **Copy Number Variation (CNV)**
- **ChIP-on-chip (e.g. DNA methylation, transcription factor binding sites)**
- **Custom Arrays**

Transcriptome Analyses

- **Whole Genome Expression for every known or partly known genome**
- **Micro RNAs**
- **Splice Variants**
- **Custom Arrays**

Agilent InkJet Printing Technology breakthrough
- Sensitivity and Flexibility



Advantages

- Free content selection
- High sensitivity
- Cost efficient

Agilent Platform



Scanner upgrade


Scanner resolution after upgrade: 2 μ m, 3 μ m + 5 μ m, 10 μ m

Available tiling arrays formats after upgrade:

1 x 1M, 2 x 400K, 4 x 180K, 8 x 60K

+

1 x 244K, 2 x 105K, 4 x 44K, 8 x 15K



iScan (BeadStation) Illumina




Genome Analysis

- Comparative Genomic Hybridization (CGH)
- Copy Number Variation (CNV)
- CHIP-on-chip (e.g. DNA methylation, transcription factor binding sites)
- Custom Arrays

Transcriptome Analyses

- Whole Genome Expression
- Micro RNAs
- Splice Variants
- Custom Arrays



iScan (BeadStation) Illumina




SNP Genotyping

SNP-CGH:

Loss of Heterozygosity (LOH)


Copy neutral LOH (e.g uniparental disomy)



+

Flexible custom genotyping for fine mapping studies or diagnostics:

96, 384, 768, 1536, 3072 60.000 SNPs per sample




iScan (BeadStation) Illumina




Whole Genome Association Studies with up to 1 Million SNPs

Haplotype tag (tag) SNPs capture most of the
haplotype structure / variation
within an haplotype block




International HAPMAP Project:
tag SNPs that uniquely identify common haplotypes
INCREASE STATISTICAL POWER




New England Journal of Medicine; Medical Uses of Statistics;
3rd Edition; Identifying Disease Genes in Association Studies
(Dan L. Nicolae, **Thorsten Kurz**, and Carole Ober).

Barrett JC, Cardon LR (2006) Evaluating coverage of
genome-wide association studies. Nat Genet 38:659-62




Genome Analyzer II~~x~~


Illumina (Solexa)



Deep Sequencing

Principle





Genome Analyzer II_x Illumina (Solexa)






Deep Sequencing / Dimensions

Flow Cell

17mm x 66mm


1.4mm wide channels



1000 molecules per 1µm cluster = up to 150.000 clusters per tile = 120 tiles per lane

Per Flow Cell:

**8 lanes = 960 tiles = 1 50.000.000 clusters = 120.000.000 reads = 14 - 18 GB high-quality output (2x75bp)
= 5TB raw data = 9.5 days run time**



Genome Analyzer II_x Illumina (Solexa)



Deep Sequencing / Applications

<u>Category</u>	<u>Examples of applications</u>
Complete genome resequencing	Comprehensive polymorphism and mutation discovery in individual human genomes
Reduced representation sequencing	Large-scale polymorphism discovery
Targeted genomic resequencing	Targeted polymorphism and mutation discovery
Paired end sequencing	Discovery of inherited and acquired structural variation
Metagenomic sequencing	Discovery of infectious and commensal flora
Transcriptome sequencing	Quantification of gene expression and alternative splicing; transcript annotation; discovery of transcribed SNPs or somatic mutations
Small RNA sequencing	microRNA profiling
Sequencing of bisulfite-treated DNA	Determining patterns of cytosine methylation in genomic DNA
Chromatin immunoprecipitation– sequencing (ChIP-Seq)	Genome-wide mapping of protein-DNA interactions
Nuclease fragmentation and sequencing	Nucleosome positioning
Molecular barcoding	Multiplex sequencing of samples from multiple individuals



The Core of the Core Facility Genomics

